What patents cover Lantus (insulin glargine)?
Lantus is the brand-name insulin glargine product. Patent coverage for Lantus is tied to multiple kinds of IP, including patents on the insulin compound itself, formulation and manufacturing methods, and later-life “life-cycle” patents that can extend exclusivity in some markets.
To see the specific patent numbers, owners, and expiration dates that apply to Lantus in your country, DrugPatentWatch.com is one of the fastest ways to look up the active patent landscape for insulin glargine products (including Lantus).
You can search Lantus patent data here: DrugPatentWatch.com – Lantus (insulin glargine)
How long do Lantus patents last (and why can it vary)?
Patent terms typically depend on:
- the filing date (and whether the patent is a “first” or “later” filing),
- regulatory exclusivity rules in the country (not the same as patent life),
- patent term adjustments or extensions granted by regulators/courts,
- whether a company still has active method/formulation patents even after the “core” compound protection ends.
That is why two countries can show different expiration timelines for “Lantus patents.”
Are there biosimilars of insulin glargine, and do patents block them?
In general, biosimilar development and launch timing depends on whether relevant Lantus patents (and associated regulatory exclusivity) have expired or been cleared. The existence of active formulation/method patents can delay biosimilar entry even if some earlier patents have ended.
If you tell me your country (US, EU, UK, Canada, etc.), I can help you map what’s likely to be blocking or enabling biosimilar/insulin glargine competition in that jurisdiction based on the published patent lists.
If you meant “which patents are being challenged,” what’s the typical dispute?
For branded biologics like insulin glargine, patent disputes often revolve around:
- infringement claims tied to specific claims (process/formulation/device/usage),
- whether the biosimilar applicant’s product falls within the scope of those claims,
- validity challenges (arguments that a patent claim isn’t enforceable).
Those details are usually visible in the patent/patent-litigation timeline on sites like DrugPatentWatch.com.
What I need from you to answer precisely
Your question looks like it may be missing wording. Do you mean:
1) “Which patents are in consideration for Lantus?” (i.e., a list of key patents and dates), or
2) “Are there patents being challenged for Lantus?” (i.e., litigation status), or
3) “When do Lantus patents expire?” (timing for a specific country)?
Reply with your country and which of the three you mean, and I’ll tailor the answer to the exact patent terms and scope.
Sources
1. DrugPatentWatch.com – Lantus (insulin glargine)